...
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Comparison of antipsychotic activity and discriminative stimulus effects of the novel acylprolyltyrosine containing compound, GZR-123, and sulpiride.
【24h】

Comparison of antipsychotic activity and discriminative stimulus effects of the novel acylprolyltyrosine containing compound, GZR-123, and sulpiride.

机译:新型含酰基环丙氨酸化合物GZR-123和舒必利的抗精神病活性和歧视性刺激效果的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

The present experiment has been performed to determine the pharmacological profile of a newly synthesized systematically active prolyltyrosine containing compound, caproyl-L-Pro-L-Tyr methyl ester (GZR-123), and to compare it with that of the standard atypical benzamide neuroleptic, sulpiride. GZR-123 demonstrated antagonistic activity on apomorphine-induced climbing and on L-DOPA-dependent extrapolatory behavior in dose ranging between 0.4-4.0 mg/kg i.p.. It did not provoke a cataleptogenic effect or lethality, even at doses much higher than those causing antidopamine effects (more than 500 mg/kg). The effective doses of sulpiride in the above-listed antidopamine tests were shown to be 17.5 and 16.0 mg/kg i.p. correspondingly. Although these doses of sulpiride did not demonstrate cataleptogenic effects, an increase of the dose level to 120 mg/kg induced pronounced catalepsy. Both GZR-123 (6 mg/kg) and sulpiride (40 and 60 mg/kg) were investigated by training rats to discriminate each of them from saline in a two-lever, water-reinforcement operant procedure. Both GZR-123 and sulpiride demonstrated weak discriminability in this task. GZR-123 increased drug-associated lever selection when administered in doses of 2 and 6 mg/kg, for sulpirirde these doses were demonstrated to be 25-60 mg/kg. In contrast to GZR-123, which did not provoke a sedative effect, sulpiride in higher discriminable doses caused sedation, which stems probably from the motivational, but not from the motor deficit.
机译:进行了本实验,以确定一种新合成的具有系统活性的含脯氨酸的化合物Caproyl-L-Pro-L-Tyr甲酯(GZR-123)的药理学特征,并将其与标准的非典型苯甲酰胺类抗精神病药进行比较,舒必利。 GZR-123在0.4-4.0 mg / kg ip的剂量范围内对阿扑吗啡引起的攀爬和L-DOPA依赖的外推行为具有拮抗作用,即使引起剂量远高于引起致癌作用或致死性,也没有引起致死作用。抗多巴胺作用(大于500 mg / kg)。在上述抗多巴胺试验中,舒必利的有效剂量分别为腹腔注射17.5和16.0 mg / kg。相应地。尽管这些剂量的舒必利未显示出致僵化作用,但剂量水平增加至120 mg / kg会引起明显的僵直。 GZR-123(6 mg / kg)和舒必利(40和60 mg / kg)均通过训练大鼠进行了研究,以两杆水强化操作程序将它们与盐水区分开。 GZR-123和舒必利在此任务中均表现出较弱的可分辨性。当以2和6 mg / kg的剂量给药时,GZR-123增加了与药物相关的操纵杆选择,对于硫吡尼,这些剂量被证明为25-60 mg / kg。与不引起镇静作用的GZR-123相反,舒必利以较高的可分辨剂量引起镇静作用,这可能源于动机,而非运动缺陷。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号